{"entity":{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","aka":[],"tldr":"Surgeon who chairs the NRG Oncology breast committee and co-led the KATHERINE and B-42 trials.","summary":"Eleftherios Mamounas (Orlando Health) chairs the NRG Oncology Breast Committee and was NSABP protocol chair for B-42 (extended letrozole) and co-chair of KATHERINE, which established adjuvant T-DM1 for residual disease after neoadjuvant therapy. He has led work using the 21-gene assay to predict locoregional recurrence and radiotherapy benefit. His current trials test omission of surgery and radiotherapy after excellent neoadjuvant response.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP"}],"tags":["breast","surgery","nrg-oncology"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine"],"companies":[],"institutions":["orlando-health-cancer-institute"],"pathways":[],"terms":[],"trials":["katherine"],"people":[],"bottlenecks":[],"keyPapers":["paper-katherine-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Comprehensive Breast Program, Orlando Health Cancer Institute; Chair, NRG Oncology Breast Committee","institutionId":"orlando-health-cancer-institute","specialisms":["Breast surgical oncology","Adjuvant and neoadjuvant trials","Genomic risk assays","Cooperative-group leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP"}],"papers":[{"title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1814017"},{"title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30621-1"}]},"route":"/people/eleftherios-mamounas/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"orlando-health-cancer-institute","kind":"institution","name":"Orlando Health Cancer Institute","route":"/institutions/orlando-health-cancer-institute/"}],"trial":[{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/"}],"paper":[{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/"}]}}